Compare Revvity Inc (RVTY) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while YieldMax Universe Fund of Option Income ETFs trades at $7.62 (market cap $364M). The key difference: Revvity Inc is far larger — about 46.6× YieldMax Universe Fund of Option Income ETFs's market cap, and Revvity Inc pays a 0.18% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| RVTY | YMAX | |
|---|---|---|
Market Cap | $16.98B | $364M |
Volume | 1,456,900 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $157.36 | $12.98 |
52-Week Low | $82.26 | $7.27 |
Typical Hold Time | 12 Days | 56 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
YMAX trades at $7.61, up 1.06% with a bearish technical outlook. The ETF shows persistent NAV erosion despite weekly distributions, with the share price declining 22.7% year-to-date. Recent portfolio adjustments and a 40%+ annualized yield highlight structural concerns about distribution sustainability. Technical indicators show bearish moving averages and neutral oscillators with support at $7 and resistance at $8.
The outlook remains cautious due to ongoing principal erosion and high fees. While the high yield attracts income investors, the fund-of-funds structure adds layered costs. Analyst sentiment is neutral to bearish, with concerns about long-term viability outweighing short-term income benefits. Key risks include distribution policy sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
